Andrew Elnatan - Sellas Life Chemistry, Affairs
| SLS Stock | USD 0.87 0.01 1.16% |
Executive
Andrew Elnatan is Chemistry, Affairs of Sellas Life Sciences
| Address | Times Square Tower, New York, NY, United States, 10036 |
| Phone | 646 200 5278 |
| Web | https://www.sellaslifesciences.com |
Sellas Life Management Efficiency
The company has Return on Asset of (1.2915) % which means that on every $100 spent on assets, it lost $1.2915. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (8.8806) %, meaning that it generated no profit with money invested by stockholders. Sellas Life's management efficiency ratios could be used to measure how well Sellas Life manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Sellas Life's Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 4.92 in 2024, whereas Return On Tangible Assets are likely to drop (9.11) in 2024. At this time, Sellas Life's Intangibles To Total Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.07 in 2024, whereas Total Assets are likely to drop slightly above 5.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carter King | Protagonist Therapeutics | 53 | |
| Michele PMP | Iovance Biotherapeutics | N/A | |
| MBA MBA | Iovance Biotherapeutics | 67 | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| Sara Pellegrino | Iovance Biotherapeutics | N/A | |
| PharmD Rasbach | Zentalis Pharmaceuticals Llc | 44 | |
| Hequn Yin | Iovance Biotherapeutics | 59 | |
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Andrea JD | Zentalis Pharmaceuticals Llc | 43 | |
| Asif Ali | Protagonist Therapeutics | 50 | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
| Ingmar MD | Zentalis Pharmaceuticals Llc | 49 | |
| Matthew JD | Protagonist Therapeutics | 53 | |
| Bo Chao | Puma Biotechnology | N/A | |
| Kimberly Freeman | Zentalis Pharmaceuticals Llc | N/A | |
Management Performance
| Return On Equity | -8.88 | ||||
| Return On Asset | -1.29 |
Sellas Life Sciences Leadership Team
Elected by the shareholders, the Sellas Life's board of directors comprises two types of representatives: Sellas Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sellas. The board's role is to monitor Sellas Life's management team and ensure that shareholders' interests are well served. Sellas Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sellas Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Esq, General VP | ||
| Jrg Breitkopf, Head Operations | ||
| ScD MD, President, Founder | ||
| Barbara Wood, Gen VP | ||
| Andrew Elnatan, Chemistry, Affairs | ||
| Robert Francomano, Senior Officer | ||
| Stacy Yeung, Associate VP | ||
| MBA MD, Senior Development | ||
| John CPA, Sr Officer |
Sellas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sellas Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.88 | ||||
| Return On Asset | -1.29 | ||||
| Current Valuation | 40.93 M | ||||
| Shares Outstanding | 70.38 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 7.36 % | ||||
| Number Of Shares Shorted | 9.05 M | ||||
| Price To Book | 3.86 X | ||||
| Price To Sales | 26.90 X | ||||
| Gross Profit | 900 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.